Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: STAG3L5P-PVRIG2P-PILRB (ImmuneEditome ID:101752399)

1. Gene summary of enriched editing regions for STAG3L5P-PVRIG2P-PILRB

Gene summary

Gene information	Gene symbol	STAG3L5P-PVRIG2P-PILRB
	Gene ID	101752399
	GeneSynonyms	FDFACT\|LOC101735302-LOC101752334-PILRB\|PILRB
	GeneCytomap	7q22.1
	GeneType	ncRNA
	GeneDescription	Activating receptor PILR-beta\|Cell surface receptor FDFACT\|LOC101735302-LOC101752334-PILRB readthrough\|Paired immunoglobulin-like type 2 receptor beta
	GeneModificationdate	20230329
	UniprotID	.
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr7:100343433-100344073:+	ENST00000310771.7	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	Charlie7,AluY,AluSc	chr7:100343433-100344073:+.alignment
chr7:100343433-100344073:+	ENST00000444874.4	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	Charlie7,AluY,AluSc	chr7:100343433-100344073:+.alignment
chr7:100343433-100344073:+	ENST00000470714.4	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	Charlie7,AluY,AluSc	chr7:100343433-100344073:+.alignment
chr7:100343433-100344073:+	ENST00000483329.5	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	Charlie7,AluY,AluSc	chr7:100343433-100344073:+.alignment
chr7:100354408-100354674:+	ENST00000310771.7	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	AluSx	chr7:100354408-100354674:+.alignment
chr7:100354408-100354674:+	ENST00000444874.4	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	AluSx	chr7:100354408-100354674:+.alignment
chr7:100354408-100354674:+	ENST00000472646.1	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	AluSx	chr7:100354408-100354674:+.alignment
chr7:100359758-100360053:+	ENST00000310771.7	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	AluSc	chr7:100359758-100360053:+.alignment
chr7:100359758-100360053:+	ENST00000444874.4	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	AluSc	chr7:100359758-100360053:+.alignment
chr7:100361016-100366186:+	ENST00000310771.7	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	L1MB2,AluSp,AluSx1,L2b,LTR47A,AluYm1,AluSz,AluSz6,AluJo,AluSx,AluSc	chr7:100361016-100366186:+.alignment
chr7:100361016-100366186:+	ENST00000444874.4	ENSG00000272752.4	STAG3L5P-PVRIG2P-PILRB	ncRNA_intronic	L1MB2,AluSp,AluSx1,L2b,LTR47A,AluYm1,AluSz,AluSz6,AluJo,AluSx,AluSc	chr7:100361016-100366186:+.alignment

Top

2. Tumor-specific enriched editing regions for STAG3L5P-PVRIG2P-PILRB

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	COAD	Path	EAG	1.0155e-02	5.3093e-03	-0.3394

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for STAG3L5P-PVRIG2P-PILRB

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for STAG3L5P-PVRIG2P-PILRB

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB

ESCA

EAG

ENSG00000111731.8

chr12

22456970:22458585:22459491:22459542

-0.3095

2.7092e-02

4.2606e-06

-0.4261

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184

Macrophages_M2

GSVA_HALLMARK_UV_RESPONSE_UP

chr7:100361016-100366186:+

ESCA

EER

ENSG00000110628.9

chr11

2902282:2902364:2903298:2903489:2903213:2903489

0.2346

4.4503e-02

4.8973e-06

0.4082

ADAR;BUD13;FBL;FUS;HNRNPC;HNRNPL;PRPF8;SF3B4;TAF15

T_cells_gamma_delta

GSVA_HALLMARK_SPERMATOGENESIS

ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB

ESCA

EAG

ENSG00000119185.8

chr2

9419989:9420100:9422478:9422566

-0.3960

2.2454e-03

1.4129e-06

-0.4128

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

ITGB1BP1

T_cells_CD4_memory_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

5. Enriched editing regions and immune infiltration for STAG3L5P-PVRIG2P-PILRB

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr7:100361016-100366186:+	BLCA	EER	T_cells_CD4_memory_activated	2.8753e-03	0.4091
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	BLCA	EAG	T_cells_follicular_helper	1.0608e-02	0.2954
chr7:100354408-100354674:+	BRCA	EER	Monocytes	4.7274e-02	0.1391
chr7:100361016-100366186:+	BRCA	EER	T_cells_CD8	7.7863e-03	0.1989
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	BRCA	EAG	T_cells_CD8	1.0404e-02	0.1376
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	CESC	EAG	B_cells_memory	2.9895e-02	0.2986
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	COAD	EAG	Dendritic_cells_activated	1.3601e-04	0.4765
chr7:100343433-100344073:+	ESCA	EER	Macrophages_M2	1.3085e-02	-0.5444
chr7:100354408-100354674:+	ESCA	EER	T_cells_regulatory_(Tregs)	2.3620e-02	-0.2561
chr7:100361016-100366186:+	ESCA	EER	Macrophages_M2	1.5374e-02	0.2130
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	ESCA	EAG	Macrophages_M2	3.5841e-02	0.1763
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	HNSC	EAG	T_cells_follicular_helper	4.9975e-02	-0.3082
chr7:100361016-100366186:+	KIRC	EER	T_cells_CD4_memory_activated	8.3052e-03	-0.3223
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	KIRC	EAG	T_cells_gamma_delta	3.7954e-03	0.2815
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	KIRP	EAG	Mast_cells_activated	7.4877e-03	0.3006
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LAML	EAG	Mast_cells_resting	1.6326e-02	-0.2103
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LGG	EAG	Macrophages_M0	6.3326e-06	0.6900
chr7:100361016-100366186:+	LUAD	EER	Dendritic_cells_activated	3.0932e-05	0.4242
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LUAD	EAG	Dendritic_cells_activated	7.5645e-03	0.2248
chr7:100361016-100366186:+	LUSC	EER	B_cells_memory	8.2646e-04	0.3733
chr7:100354408-100354674:+	OV	EER	Eosinophils	3.0936e-02	0.2789
chr7:100361016-100366186:+	OV	EER	T_cells_gamma_delta	4.1445e-02	0.1539
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	OV	EAG	T_cells_gamma_delta	1.2479e-02	0.1777
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	PRAD	EAG	T_cells_follicular_helper	3.3299e-02	0.3016
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	SKCM	EAG	Macrophages_M1	3.8757e-02	-0.2273
chr7:100354408-100354674:+	STAD	EER	Macrophages_M1	3.3457e-03	0.3436
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	STAD	EAG	Dendritic_cells_activated	3.9671e-02	0.1373
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	THCA	EAG	B_cells_naive	1.7702e-02	0.4103

Top

6. Enriched editing regions and immune gene sets for STAG3L5P-PVRIG2P-PILRB

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.7141e-05	0.4672
chr7:100361016-100366186:+	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.0619e-03	0.4067
chr7:100354408-100354674:+	BRCA	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	4.9371e-03	0.1961
chr7:100361016-100366186:+	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	5.2960e-04	0.2572
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	CESC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.0699e-02	0.3479
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	COAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.6391e-02	-0.3113
chr7:100361016-100366186:+	ESCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	8.3515e-04	0.2906
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	ESCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	4.9373e-04	0.2887
chr7:100343433-100344073:+	ESCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	1.9037e-02	-0.5190
chr7:100354408-100354674:+	ESCA	GSVA_HALLMARK_HYPOXIA	EER	5.3919e-03	0.3122
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	HNSC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.1088e-02	-0.3592
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	6.7330e-03	-0.2642
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	KIRP	GSVA_HALLMARK_HEME_METABOLISM	EAG	2.0171e-02	-0.2627
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LAML	GSVA_HALLMARK_SPERMATOGENESIS	EAG	2.1686e-02	-0.2012
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LGG	GSVA_HALLMARK_DNA_REPAIR	EAG	3.3029e-03	0.4895
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LUAD	GSVA_HALLMARK_COAGULATION	EAG	5.4105e-03	-0.2339
chr7:100361016-100366186:+	LUAD	GSVA_HALLMARK_MYOGENESIS	EER	8.7772e-03	-0.2747
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LUSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	3.0149e-03	0.2481
chr7:100361016-100366186:+	LUSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	5.6731e-04	0.3839
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	OV	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	9.9332e-03	0.1833
chr7:100354408-100354674:+	OV	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.4350e-02	0.3146
chr7:100361016-100366186:+	OV	GSVA_HALLMARK_NOTCH_SIGNALING	EER	2.7843e-02	0.1658
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	PAAD	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	2.0601e-02	0.4432
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.6268e-02	-0.2969
chr7:100354408-100354674:+	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	4.4393e-02	0.2394
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	STAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.5733e-02	-0.1609
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	THCA	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.2420e-02	0.4304
chr7:100361016-100366186:+	UCEC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	2.6601e-02	0.4187

Top

7. Enriched editing regions and drugs for STAG3L5P-PVRIG2P-PILRB

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	BLCA	A.770041	EAG	2.4396e-02	-0.2615
chr7:100361016-100366186:+	BLCA	JNJ.26854165	EER	1.7376e-02	-0.3318
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	BRCA	A.443654	EAG	9.8877e-03	-0.1385
chr7:100361016-100366186:+	BRCA	BI.2536	EER	6.5494e-03	-0.2031
chr7:100354408-100354674:+	BRCA	GNF.2	EER	2.7792e-05	-0.2889
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	CESC	GNF.2	EAG	8.1928e-05	-0.5142
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	COAD	KIN001.135	EAG	3.0760e-04	-0.4537
chr7:100343433-100344073:+	ESCA	IPA.3	EER	3.6201e-02	-0.4707
chr7:100361016-100366186:+	ESCA	ABT.888	EER	4.4598e-03	0.2488
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	ESCA	MG.132	EAG	1.6900e-03	-0.2612
chr7:100354408-100354674:+	ESCA	Gefitinib	EER	5.4848e-04	-0.3825
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	GBM	BMS.708163	EAG	3.0375e-02	-0.3665
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	HNSC	AMG.706	EAG	4.0624e-02	0.3212
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	KIRC	GSK.650394	EAG	2.4736e-02	0.2201
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	KIRP	AZ628	EAG	8.3082e-05	-0.4306
chr7:100361016-100366186:+	KIRP	AZD.0530	EER	5.4342e-03	-0.3733
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LAML	EHT.1864	EAG	1.6694e-03	0.2731
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LGG	Docetaxel	EAG	1.7301e-03	-0.5173
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LUAD	Bexarotene	EAG	2.4417e-04	0.3053
chr7:100361016-100366186:+	LUAD	BMS.708163	EER	2.8240e-04	-0.3740
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	LUSC	AP.24534	EAG	2.9228e-02	0.1837
chr7:100361016-100366186:+	LUSC	CCT007093	EER	2.8818e-03	0.3352
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	OV	Elesclomol	EAG	3.1760e-03	-0.2092
chr7:100359758-100360053:+	OV	MG.132	EER	1.7744e-02	-0.4371
chr7:100361016-100366186:+	OV	ATRA	EER	4.3556e-02	0.1523
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	PAAD	BX.795	EAG	5.3653e-03	0.5206
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	PRAD	Bexarotene	EAG	2.8111e-02	0.3106
chr7:100361016-100366186:+	STAD	Cytarabine	EER	2.4087e-02	-0.1568
chr7:100359758-100360053:+	STAD	CMK	EER	3.9226e-03	-0.3828
chr7:100354408-100354674:+	STAD	Bortezomib	EER	2.9342e-02	-0.2588
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	STAD	KU.55933	EAG	1.4208e-02	-0.1633
chr7:100343433-100344073:+	STAD	Methotrexate	EER	5.8279e-03	-0.3773
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	THCA	Bryostatin.1	EAG	2.4220e-02	0.3916
chr7:100361016-100366186:+	UCEC	AZD6244	EER	3.2439e-02	-0.4052
ENSG00000272752.4,STAG3L5P-PVRIG2P-PILRB	UCEC	AZD6244	EAG	6.9494e-03	-0.4420

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType